Author:
Millward M.J.,Newell D.R.,Mummaneni V.,Igwemezie L.N.,Balmanno K.,Charlton C.J.,Gumbrell L.,Lind M.J.,Chapman F.,Proctor M.,Simmonds D.,Cantwell B.M.J.,Taylor G.A.,McDaniel C.,Winograd B.,Kaul S.,Barbaiya R.H.,Calvert A.H.
Reference13 articles.
1. Second generation analogs of etoposide and mitomycin C;Doyle;Cancer Treat Rev,1990
2. Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30;Rose;Invest New Drugs,1990
3. World Health Organisation. Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, Offset Publication 48.
4. Phase I evaluation of a water soluble etoposide prodrug, etoposide phosphate, given as a 5 minute infusion on days 1, 3, 5 in patients with solid tumors;Budman;J Clin Oncol,1993
5. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3 and 5;Fields;Clin Cancer Res,1995
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献